

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 May 2020 (22.05.2020)



(10) International Publication Number
WO 2020/102387 A1

(51) International Patent Classification:

C07K 16/46 (2006.01) A61K 39/395 (2006.01)
C07K 16/30 (2006.01) A61P 35/00 (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:

PCT/US2019/061226

(22) International Filing Date:

13 November 2019 (13.11.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/760,801 13 November 2018 (13.11.2018) US
62/855,580 31 May 2019 (31.05.2019) US
62/898,991 11 September 2019 (11.09.2019) US
62/931,478 06 November 2019 (06.11.2019) US

(71) Applicant: COMPASS THERAPEUTICS LLC

[US/US]; 245 First Street, Cambridge, MA 02142 (US).

(72) Inventors: GONG, Bing; c/o Compass Therapeutics LLC,

245 First Street, Cambridge, MA 02142 (US). RENNARD, Rachel; c/o Compass Therapeutics LLC, 245 First Street, Cambridge, MA 02142 (US). OLIPHANT, Amanda, Frank; c/o Compass Therapeutics LLC, 245 First Street, Cambridge, MA 02142 (US). LEUNG, Cheuk, Lun; c/o Compass Therapeutics LLC, 245 First Street, Cambridge, MA 02142 (US). WOLF, Benjamin, Jacob; c/o Compass Therapeutics LLC, 245 First Street, Cambridge, MA 02142 (US). ESKIOCAK, Ugur; c/o Compass Therapeutics LLC, 245 First Street, Cambridge, MA 02142 (US). BAKHRU, Pearl; c/o Compass Therapeutics LLC, 245 First Street, Cambridge, MA 02142 (US). ALBU, Diana, I.; c/o Compass Therapeutics LLC, 245 First Street, Cambridge, MA 02142 (US).

(74) Agent: WARD, Donna T. et al.; DT Ward, PC, 142A Main

Street, Groton, MA 01450 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: MULTISPECIFIC BINDING CONSTRUCTS AGAINST CHECKPOINT MOLECULES AND USES THEREOF

(57) Abstract: The present disclosure relates to compositions and methods for inhibiting tumor evasion by reducing immune checkpoint suppression. In some embodiments, provided herein are compositions that block the interaction between PD-1 and its ligand (e.g., PD-1 and/or PD-L2) while promoting the interaction of the cells on which PD-1 and its ligand are expressed. Also provided are methods of using such compositions.

WO 2020/102387 A1